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Abstract: Background. Hepatic encephalopathy is a chronically
debilitating complication of hepatic cirrhosis. The efﬁcacy of Rifaxi-
min, a minimally absorbed antibiotic, is well documented in the
treatment of acute hepatic encephalopathy, but its efﬁcacy for pre-
vention of the disease has not been established. Methods. In this ran-
domized, double-blind, placebo-controlled trial, we randomly
assigned 299 patients who were in remission from recurrent hepatic
encephalopathy resulting from chronic liver disease to receive either
Rifaximin, at a dose of 550 mg twice daily (140 patients), or placebo
(159 patients) for 6 months. The primary efﬁcacy end point was the
time to the ﬁrst breakthrough episode of hepatic encephalopathy.
The key secondary end point was the time to the ﬁrst hospitalisation
involving hepatic encephalopathy. Results. Rifaximin signiﬁcantly
reduced the risk of an episode of hepatic encephalopathy, as com-
pared with placebo, over a 6-month period (hazard ratio with Rifax-
imin, 0.42; 95% conﬁdence interval [CI], 0.28–0.64; P < 0.001). A
breakthrough episode of hepatic encephalopathy occurred in 22.1%
of patients in the Rifaximin group, as compared with 45.9% of
patients in the placebo group. A total of 13.6% of the patients in
the Rifaximin group had a hospitalization involving hepatic enceph-
alopathy, as compared with 22.6% of patients in the placebo group,
for a hazard ratio of 0.50 (95% CI, 0.29–0.87; P = 0.01). More than
90% of patients received concomitant Lactulose therapy. The inci-
dence of adverse events reported during the study was similar in
the two groups, as was the incidence of serious adverse events. Con-
clusions. Over a 6-month period, treatment with Rifaximin main-
tained remission from hepatic encephalopathy more effectively
than did placebo. Rifaximin treatment also signiﬁcantly reduced
the risk of hospitalization involving hepatic encephalopathy. (Clini-
calTrials.gov number, NCT00298038).
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Open access under CC BY-NC-ND license.Hepatic Encephalopathy (HE) is a complex neuropsychiatric
syndrome that occurs in patients with liver disease [1]. Its man-
ifestations can vary widely from mild neurocognitive distur-
bances to severe confusion and coma. In acute liver failure, the
hallmark of HE is an increase in intracranial pressure which can
result in death from cerebral herniation. In patients with cirrho-
sis, up to 70% of patients in some series have evidence of minimal
hepatic encephalopathy. The admission of cirrhotic patients to
the hospital with a complication of cirrhosis such as HE is associ-
ated with a change in the natural history of cirrhosis, with 5-year
mortality rates of up to 40% [2].
In a well-conducted, adequately powered, multi-centre study
performed predominantly in the United States and Russia, Bass
et al. randomised 299 cirrhotic patients to receive Rifaximin or
placebo for 6 months [3]. Rifaximin is a poorly absorbed antibiotic
which has a very wide range of anti-bacterial activity extending
from gram negative to gram positive and anaerobic organisms.
At the time of randomisation, these patients had recovered from
the episode of HE and the question they addressed in this study
was whether treatment of these patients with Rifaximin would
allow maintenance of remission compared with placebo. Their
data clearly show that treatment with Rifaximin reduced time
to ﬁrst episode of HE and also time to ﬁrst HE related hospitalisa-
tion in this population of patients. It is not clear from the paper
whether Rifaximin prevented the occurrence of a precipitating
event or de novo HE episodes as acute episodes of HE are usually
due to a precipitating illness. It is worth emphasising that this
study did not address treatment of an acute episode of HE or min-
imal HE patients and restricted the entry to patients with a MELD
score of less than 25. The reason for this MELD criteria restriction
is not clear but important as Rifaximin is bio-available and phar-
macokinetics in the context of more severe disease needs further
clariﬁcation. It is of note and perhaps surprising that despite a
reduction in hospital admissions from HE, there was no effect
on survival. It is also important to recognise that over 90% patients
in both groups were on treatment with Lactulose in addition to
Rifaximin and whether there is a synergistic action of the two
remains unclear. The investigators reported extensive safety data
and apart from 2 cases of Clostridium difﬁcile infections in the Rif-
aximin treated group there were no major issues. Obviously, as
the drug affects a wide range of bacteria in the gut, the risk of
super-infection is a theoretical possibility which will need to be
addressed in the post-marketing surveillance studies [4]. There-
fore, the current indications are limited to this groups of patients
perhaps using a combination of Lactulose with Rifaximin.10 vol. 53 j 580–582
Fig. 1. A hypothetical framework to explain the current thinking about the pathogenesis of hepatic encephalopathy and how the Rifaximin data ﬁt into the
hypothesis. Ammonia can directly result in brain swelling and HE but it can also activate neutrophils and reduction in its levels reduces brain inﬂammation. Increased gut
permeability, bacterial overgrowth, and increased gut transit time leads to increased bacterial translocation which leads to activation of systemic and brain inﬂammation.
The role of alterations in the pathogen recognition receptors have not been clariﬁed but the beneﬁcial effects of Rifaximin argue strongly for an important role for these in
orchestrating brain inﬂammation in liver failure.
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studies of Norﬂoxacin, which is a more selective, poorly absorbed
antibiotic with anti-bacterial activity predominantly on the gram
negative organisms [5]. In a recently published study, patients
with advanced cirrhosis and ascites were randomised to receive
Norﬂoxacin or placebo. Norﬂoxacin administration reduced the
1-year probability of developing spontaneous bacterial peritoni-
tis and hepatorenal syndrome and, improved the 3-month and
the 1-year survival compared with placebo. There are several par-
allels in the two studies where gut bacteria is the target using
two different agents with different microbiological proﬁles but
the essential premise is directed at prevention of a complication
of cirrhosis; HE with Rifaximin and hepatorenal syndrome with
Norﬂoxacin. Despite larger number of patients included in the
Rifaximin study, the lack of effect on survival is difﬁcult to under-
stand but may indicate a population at much lower risk of death
and lack of power of the study to address this end point. Alterna-Journal of Hepatology 201tively, it may indicate that the much broader anti-bacterial prop-
erty of Rifaximin is an issue which should be resolved in a head-
to-head study. Nevertheless, these studies stress the role of the
‘gut bacteria’ as an important therapeutic target and an alterna-
tive strategy includes probiotics [6] which has been shown to
be effective in patients with minimal HE. More recently, a very
different approach is being used to target the ‘gut’ using non-
absorbable charcoal, which is being trialled in patients with min-
imal HE [7].
For over 100 years, ammonia has been thought to be central in
the pathogenesis of HE but more recently an important role of
inﬂammation has been hypothesised [8]. Studies in patients with
acute liver failure and cirrhosis have shown incontrovertibly that
peripheral and brain inﬂammatory responses are important in
modulating the effect of hyperammonemia [9]. In fact, reduction
in ammonia using Ornithine phenylacetate in animal models was
recently shown to reduce brain inﬂammation [10]. No data are0 vol. 53 j 580–582 581
International Hepatology
presented in this paper about the effect of Rifaximin on ammonia
levels leading one to suggest that the action of Rifaximin in this
context is related to alteration in gut bacterial translocation.
How gut bacterial translocation may make patients more suscep-
tible to HE is unclear but may point to clues regarding the path-
ogenesis and treatments of HE (Fig. 1) [11]. In conclusion, the
study by Bass et al. is a trailblazer for trials in HE and the recent
approval for use of Rifaximin by the FDA for maintenance of
remission of HE provides the impetus for development of other
new compounds for HE which has remained a condition without
any speciﬁc treatment. The data provide novel insights into the
pathogenesis of HE which will lead to the identiﬁcation of new
targets of therapy.Conﬂict of interest
University College London has licensed its invention, Ornithine
phenylacetate to Ocera Therapeutics.
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